I’m not sure about you, but I’m getting tired of Steve Jobs. Sure, he was an innovation icon. But, in my view, the media and pundits are creating unrealistic expectations hyping and promoting the Jobs/Branson/Musk iconography.
Yumanity Therapeutics, a drug developer focused on diseases caused by protein misfolding, has raised $45 million in Series A funding. Fidelity Management & Research Company led the round with participation from Redmile Group, Alexandria Venture Investments, Biogen, Sanofi-Genzyme BioVentures and Dolby Family Ventures.
Bobby Gattuso became a startup founder while an undergraduate at Towson University.
Hop Theory’s sachets that bring beer up to craft levels got early traction through Kickstarter and national press hits.
A senior Google executive, Jeff Huber, will become the CEO of Grail, the high-profile company launched in January to develop and commercialize cancer blood tests.
According to Forbes, Huber’s wife, Laura, died from colon cancer last November, leaving behind two teenage children. “That’s a big part of why I’m taking this up,” Huber told the magazine.
“You are cordially invited to the “SBIR and STTR Federal Funding Mechanisms for Improving the Reach of Behavioral Science” seminar at the Society of Behavioral Medicine (SBM) 2016 Annual Meeting & Scientific Sessions. National Cancer Institute SBIR (NCI SBIR) Development Center Program Director Dr. Patricia Weber will be leading the seminar with presenters from NIH, including NCI and NHLBI, a HealthTech investment CEO and a small business entrepreneur. The session will include a range of topics such as an overview of the SBIR/STTR program goals, how NCI and NHLBI work to help with the commercialization process, how SBIR/STTR funding can advance behavioral science, investor perspectives on behavioral health products, and perspectives from an awardee.”
It’s comforting to believe that the world of venture funding is a meritocracy.
It’s comforting to believe that a founder has a good idea, pitches successfully and gets money from a VC to turn said idea into a business.
10x Genomics has announced two new sequencing partnerships with Qiagen and Illumina.
Yesterday, 10x said that it is partnering with Qiagen to co-develop and co-market next-generation sequencing and single-cell biology analysis workflows and informatics solutions.
Enterprising startups are disrupting incumbent players in industries as diverse as publishing, entertainment and personal finance. Healthcare is far from immune to this tech-driven business trend— across the industry, young and innovative firms are giving legacy systems a run for their money.
At the heart of the change sweeping across the healthcare business is data.
President Obama’s proposed nearly $4.15 trillion budget for the 2017 federal fiscal year offers small increases for NIH and FDA, sets up a showdown over sources of NIH funding, and directs big dollars to research programs championed by the administration, in a spending plan unlikely to face smooth sailing in Congress.
Obama is seeking $33.1 billion in overall program level funding for NIH, up about $1 billion or 3% from the current fiscal year, during which the president and Congress agreed to a $2 billion spending hike for the agency.
On Feb. 8, 2016, the National Cybersecurity Center of Excellence (NCCoE) celebrated its move to expanded new facilities with a building dedication and expert panel discussions featuring senior elected and government officials and the CEOs and presidents of several large companies.
NCCoE staff and partners demonstrated several of the center’s current projects that address challenges faced by many organizations, such as access control, mobile device security, online identity authentication, data integrity, situational awareness, and IT asset management. The 5,574 square-meter (60,000 square-foot) facility has 22 labs, including two large enough to hold vehicles for cybersecurity testing.